Novavax (NVAX) has been struggling to convince the market that its COVID era gains can translate into a durable vaccine business, and the stock’s recent slide reflects those doubts. See our latest ...

Ampoules of Novavax's COVID-19 vaccine prepared in Berlin, Germany. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma ...

US FDA's vaccine director Dr. Vinay Prasad wrote a memo to their staff that claimed multiple child deaths were related to ...

Novavax, Inc. reported 3Q25 EPS loss & declining revenue, but beat revenue expectations & reaffirmed its FY25 guidance. Read ...

Novavax’s closely watched COVID-19 vaccine is on track for full approval after additional discussions with the Food and Drug Administration, the Gaithersburg-based company said Wednesday. The news ...

Novavax, Inc. recently announced at the Jefferies London Healthcare Conference 2025 that it is shifting its focus from direct COVID-19 commercial operations to an expanded research and development ...

A medical worker prepares ampoules of the Nuvaxovid vaccine against Covid-19 by Novavax at the Tegel vaccination center on February 28, 2022 in Berlin, Germany. This story was originally published ...

The Biden administration announced Monday that it would purchase 3.2 million doses of the Novavax COVID-19 vaccine. It will be offered at no cost to states and federal partners. “We remain ...

The Food and Drug Administration (FDA) signed off Wednesday on an emergency use authorization for the Novavax COVID-19 vaccine for individuals 18 years of age and older. The Novavax vaccine is ...

GAITHERSBURG, Md., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today ...

The memo, written by FDA chief medical and scientific officer Vinay Prasad, reviewed 96 pediatric deaths and concluded that ...